Gaofeng F. Zheng

No. 79, Qingchun Rd
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Performance and additional benefits of MALDI-TOF-MS in M-protein detection in plasma cell disorders.

Performance and additional benefits of MALDI-TOF-MS in M-protein detection in plasma cell disorders.

Journal: Annals of medicine

Published: April 28, 2026

Efficacy and Safety of Low-Frequency Daratumumab Regimen in Systemic Light-Chain Amyloidosis.

Efficacy and Safety of Low-Frequency Daratumumab Regimen in Systemic Light-Chain Amyloidosis.

Journal: Cancer medicine

Published: December 11, 2025

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma.

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma.

Journal: Cancer biology & medicine

Published: October 21, 2025

Determining the factors affecting bortezomib's adverse events in the treatment of newly diagnosed multiple myeloma.

Determining the factors affecting bortezomib's adverse events in the treatment of newly diagnosed multiple myeloma.

Journal: Hematology (Amsterdam, Netherlands)

Published: September 02, 2025

Long-term follow-up of zevor-cel in patients with relapsed/refractory multiple myeloma.

Long-term follow-up of zevor-cel in patients with relapsed/refractory multiple myeloma.

Journal: Blood advances

Published: June 12, 2025

Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.

Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.

Journal: Therapeutic advances in medical oncology

Published: April 07, 2025

Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.

Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.

Journal: Annals of hematology

Published: January 15, 2025

PICALM-MLLT10 fusion gene in hematological neoplasms: clinical features, current practices, and prognoses.

PICALM-MLLT10 fusion gene in hematological neoplasms: clinical features, current practices, and prognoses.

Journal: Hematology (Amsterdam, Netherlands)

Published: November 05, 2024

When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study.

When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 07, 2024

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.

Journal: Cancer biology & therapy

Published: September 19, 2024

Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.

Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.

Journal: Targeted oncology

Published: January 31, 2024

Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.

Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.

Journal: Cancer medicine

Published: January 18, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026